Reno-prevention vs. reno-protection: A critical re-appraisal of the evidence-base from the large RAAS blockade trials after ontarget - A call for more circumspection

QJM: An International Journal of Medicine

Volumn 102, Issue 3, 2009, Pages 155-167

  Onuigbo, M A C ^a  

^a Mayo Health System   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FOSINOPRIL; FUROSEMIDE; HYDRALAZINE; IRBESARTAN; LISINOPRIL; LOSARTAN; METOPROLOL; NISOLDIPINE; PLACEBO; RAMIPRIL; TELMISARTAN;

BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EVENING DOSAGE; GLOMERULUS FILTRATION RATE; HEART PROTECTION; HUMAN; HYPERKALEMIA; HYPERTENSION; KIDNEY DISEASE; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY FUNCTION; LOW DRUG DOSE; NON INSULIN DEPENDENT DIABETES MELLITUS; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROTEINURIA; RECOMMENDED DRUG DOSE; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIDE EFFECT; TREATMENT INDICATION;

EID: 61649098176     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcn142     Document Type: Review

References (80)

1. Ondetti MA, Williams NJ, Sabo EF, Pluscec J, Weaver ER, Kocy O. Angiotensin-converting enzyme inhibitors from the venom of Bothrops jararaca. Isolation, elucidation of structure, and synthesis. Biochemistry 1971; 10:4033-9.
2. Ondetti MA, Rubin B, Cushman DW. Design of specific inhibitors of angiotensin-converting enzyme: New class of orally active antihypertensive agents. Science 1977; 196:441-4.
3. Weber MA, Byyny RL, Pratt A, Faison EP, Snavely DB, Goldberg AI, et al. Blood pressure effects of the angiotensin II receptor blocker, losartan. Arch Intern Med 1995; 155:405-11.
4. Crozier I, Ikram H, Awan N, Cleland J, Stephen N, Dickstein K, et al Losartan in heart failure. Hemodynamic effects and tolerability. Circulation 1995; 91:691-7.
5. Messerli FH, Weber MA, Brunner HR. Angiotensin II receptor inhibition. A new therapeutic principle. Arch Intern Med 1996; 156:1957-65.
6. Onuigbo M. Angiotensin II receptor antagonists: What future? South Med J 1998; 91:794-6.
7. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355:253-9. Erratum in: Lancet 2000; 356 860.
8. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329:1456-62. Erratum in: N Engl J Med 1993; 330:152.
9. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327 685-91. Erratum in: N Engl J Med 1992; 327:1768.
10. Laffel LM, McGill JB, Gans DJ. The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. North American Microalbuminuria Study Group. Am J Med 1995; 99 497-504.
11. Ruggenenti P, Perna A, Gherardi G, Garini G, Zoccali C, Salvadori M, et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 1999; 354 359-64.
12. Packer M, Poole-Wilson PA, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999; 100:2312-8.
13. Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000; 321:1440-4.
14. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355 1582-7.
15. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349:1893-906.
16. Onuigbo M, Weir MR. Evidence-based treatment of hypertension in patients with diabetes mellitus. Diabetes Obes Metab 2003; 5:13-26.
17. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, Marcantoni C, et al. AIPRD Study Group. Angiotensin-Converting Enzymne Inhibition and Progression of Renal Disease. Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int 2001; 60:1131-40.
18. Lunõ J, Barrio V, Goicoechea MA, González C, de Vinuesa SG, Gómez F, et al. Effects of dual blockade of the renin-angiotensin system in primary proteinuric nephropathies. Kidney Int Suppl 2002; 82:S47-52.
19. Rossing K, Jacobsen P, Pietraszek L, Parving HH. Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: A randomized double-blind cross-over trial. Diabetes Care 2003; 26:2268-74.
20. MacKinnon M, Shurraw S, Akbari A, Knoll GA, Jaffey J, Clark HD. Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: A systematic review of the efficacy and safety data. Am J Kidney Dis 2006; 48:8-20.
21. Jennings DL, Kalus JS, Coleman CI, Manierski C, Yee J. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: A meta-analysis. Diabet Med 2007; 24 486-93.
22. Bakris GL, Weir MR. Comparison of dual RAAS blockade and higher-dose RAAS inhibition on nephropathy progression. Postgrad Med 2008; 120:33-42.
23. Weir MR, Bakris GL. Combination therapy with Renin-Angiotensin-aldosterone receptor blockers for hypertension: How far have we come? J Clin Hypertens (Greenwich) 2008; 10 146-52.
24. Ruilope LM. Angiotensin receptor blockers: RAAS blockade and renoprotection. Curr Med Res Opin 2008; 24:1285-93.
25. Rossing P, Hommel E, Smidt UM, Parving HH. Reduction in albuminuria predicts diminished progression in diabetic nephropathy. Kidney Int Suppl 1994; 45:S145-9.
26. Ruilope LM, Jakobsen A, Heroys J, Ralph A, Rees T, Shaw M. Prospects for renovascular protection by more aggressive renin-angiotensin system control. Medscape J Med 2008; 10(Suppl):S5.
27. Toto R, Palmer BF. Rationale for combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor treatment and end-organ protection in patients with chronic kidney disease. Am J Nephrol 2008; 28:372-80.
28. Rossing K, Schjoedt KJ, Jensen BR, Boomsma F, Parving HH. Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. Kidney Int 2005; 68 1190-8.
29. Carter BL, Malone DC, Ellis SL, Dombrowski RC. Antihypertensive Drug Utilization in Hypertensive Veterans With Complex Medication Profiles. J Clin Hypertens (Greenwich) 2000; 2:172-80.
30. Nelson CR, Knapp DA. Trends in antihypertensive drug therapy of ambulatory patients by US office-based physicians. Hypertension 2000; 36:600-3.
31. Scarsi KK, Bjornson DC. The use of ACE inhibitors as renoprotective agents in Medicaid patients with diabetes. Ann Pharmacother 2000; 34:1002-6.
32. Hsu CY, Vittinghoff E, Lin F, Shlipak MG. The incidence of end-stage renal disease is increasing faster than the prevalence of chronic renal insufficiency. Ann Intern Med 2004; 141:95-101.
33. Szczech LA, Lazar IL. Projecting the United States ESRD population: issues regarding treatment of patients with ESRD. Kidney Int Suppl 2004; 90:S3-7.
34. Jones CA, Krolewski AS, Rogus J, Xue JL, Collins A, Warram JH. Epidemic of end-stage renal disease in people with diabetes in the United States population: Do we know the cause? Kidney Int 2005; 67 1684-91.
35. US Renal Data System. USRDS 2007 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease 2007. Accessed June 18, 2008. Available at http://http://www.usrds.org/ adr.htm.
36. Centers for Disease Control and Prevention (CDC). Prevalence of chronic kidney disease and associated risk factors - United States, 1999-2004. MMWR Morb Mortal Wkly Rep 2007; 56:161-65.
37. Suissa S, Hutchinson T, Brophy JM, Kezouh A. ACE-inhibitor use and the long-term risk of renal failure in diabetes. Kidney Int 2006; 69:913-19.
38. Hsu CY, McCulloch CE, Fan D, Ordoñez JD, Chertow GM, Go AS. Community-based incidence of acute renal failure. Kidney Int 2007; 72:208-12.
39. Centers for Disease Control and Prevention (CDC). Hospitalization discharge diagnoses for kidney disease-United States, 1980-2005. MMWR Morb Mortal Wkly Rep 2008; 57:309-12.
40. Casas JP, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD, et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: Systematic review and meta-analysis. Lancet 2005; 366:2026-33.
41. Alicic R, Tuttle KR. Do agents that block the RAS truly offer renoprotective effects in early stage, nonproteinuric nephropathy? Curr Hypertens Rep 2007; 9:393-402.
42. Fisman EZ, Tenenbaum A, Motro M. Losartan and diabetic nephropathy: commentaries on the RENAAL study. Cardiovasc Diabetol 2002; 1 2.
43. Svensson P, de Faire U, Sleight P, Yusuf S, Ostergren J. Comparative effects of ramipril on ambulatory and office blood pressures. A HOPE substudy. Hypertension 2001; 38:e28-32.
44. Onuigbo MA, Onuigbo NT. Late onset renal failure from angiotensin blockade (LORFFAB): A prospective thirty-month Mayo Health System clinic experience. Med Sci Monit 2005; 11:CR462-9.
45. Onuigbo MA, Onuigbo NT. Use of ultrahigh RAAS blockade: Implications for exacerbation of renal failure. Kidney Int 2006; 69:194-5.
46. Onuigbo MA, Onuigbo NT. Late-onset renal failure from RAAS blockade. Kidney Int 2006; 70:1378-9.
47. Onuigbo MA, Onuigbo NT. Late-onset renal failure from angiotensin blockade (LORFFAB) in 100 CKD patients. Int Urol Nephrol 2008; 40:233-9.
48. Onuigbo MA, Onuigbo NT. Does renin-angiotensin aldosterone system blockade exacerbate contrast-induced nephropathy in patients with chronic kidney disease? A prospective 50-month Mayo Clinic study. Ren Fail 2008; 30:67-72.
49. Onuigbo MA, Onuigbo NT. Late onset azotemia from RAAS blockade in CKD patients with normal renal arteries and no precipitating risk factors. Ren Fail 2008; 30:73-80.
50. Onuigbo MA, Onuigbo NT. Worsening renal failure in older chronic kidney disease patients with renal artery stenosis concurrently on renin angiotensin aldosterone system blockade: A prospective 50-month Mayo-Health-System clinic analysis. QJM 2008; 101:519-27.
51. Onuigbo MA, Onuigbo NT. Renal failure and concurrent RAAS blockade in older CKD patients with renal artery stenosis: An extended Mayo Clinic prospective 63-month experience. Ren Fail 2008; 30:363-71.
52. Onuigbo MA. Increasing acute renal failure (ARF) in US hospitals: Does concurrent RAAS blockade in older CKD patients have a causative role? - 3 cases of severe ARF in 3 days in a Northwestern Wisconsin Nephrology Practice. J Am Soc Nephrol 2008; 19:978A (Abstract).
53. Onuigbo MAC. RAAS blockade, renal failure, ESRD and death amongst African Americans in the AASK post-trial cohort study. Arch Intern Med 2008; 168:2383-84 (Editorial Comment).
54. Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: Effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 2008; 148:30-48.
55. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al. ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358 1547-59.
56. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345 870-8.
57. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-9.
58. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851-60.
59. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: The CHARM-Alternative trial. Lancet 2003; 362:772-6.
60. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM-overall programme. Lancet 2003; 362:759-66.
61. Rahman M, Pressel S, Davis BR, Nwachuku C, Wright JT, Jr, Whelton PK, et al. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: A report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2005; 165:936-46.
62. Parving HH, Smidt UM, Hommel E, Mathiesen ER, Rossing P, Nielsen F, et al. Effective antihypertensive treatment postpones renal insufficiency in diabetic nephropathy. Am J Kidney Dis 1993; 22 188-95.
63. Bakris GL, Weir MR, Shanifar S, Zhang Z, Douglas J, van Dijk DJ, et al. RENAAL Study Group. Effects of blood pressure level on progression of diabetic nephropathy: Results from the RENAAL study. Arch Intern Med 2003; 163:1555-65.
64. Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, et al. Collaborative Study Group. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med 2003; 138:542-9.
65. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, et al. ONTARGET investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372:547-53.
66. Onuigbo MA. Causes of renal failure in patients with type 2 diabetes mellitus. JAMA 2003; 290:1855.
67. Tsalamandris C, Allen TJ, Gilbert RE, Sinha A, Panagiotopoulos S, Cooper ME, et al. Progressive decline in renal function in diabetic patients with and without albuminuria. Diabetes 1994; 43 649-55.
68. Nosadini R, Velussi M, Brocco E, Bruseghin M, Abaterusso C, Saller A, et al. Course of renal function in type 2 diabetic patients with abnormalities of albumin excretion rate. Diabetes 2000; 49 476-84.
69. Onuigbo MA. Late onset renal failure from angiotensin blockade (LORFFAB) in 5 CKD patients with normal renal arteries without precipitating risk factors - 5 plus years later: The course of eGFR and proteinuria following discontinuation of angiotensin blockade: An extended 68-month report from a Mayo Health System Hypertension Clinic. J Am Soc Nephrol 2008; 19:942A (Abstract).
70. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42:1206-52.
71. Komenda P, Zalunardo N, Burnett S, Love J, Buller C, Taylor P, et al Conservative outpatient renoprotective protocol in patients with low GFR undergoing contrast angiography: A case series. Clin Exp Nephrol 2007; 11:209-13.
72. Louis BM, Hoch BS, Hernandez C, Namboodiri N, Neiderman G, Nissenbaum A, et al. Protection from the nephrotoxicity of contrast dye. Renal Fail 1996; 18:639-46.
73. Markowitz GS, Nasr SH, Klein P, Anderson H, Stack JI, Alterman L, et al. Renal failure due to acute nephrocalcinosis following oral sodium phosphate bowel cleansing. Hum Pathol 2004; 35:675-84.
74. Rose M, Karlstadt RG, Walker K. Renal failure following bowel cleansing with a sodium phosphate purgative. Nephrol Dial Transplant 2005; 20:1518-9.
75. Russmann S, Lamerato L, Marfatia A, Motsko SP, Pezzullo JC, Olds G, et al. Risk of impaired renal function after colonoscopy: A cohort study in patients receiving either oral sodium phosphate or polyethylene glycol. Am J Gastroenterol 2007; 102:2655-63.
76. Khurana A, McLean L, Atkinson S, Foulks CJ. The effect of oral sodium phosphate drug products on renal function in adults undergoing bowel endoscopy. Arch Intern Med 2008; 168:593-7.
77. Arora P, Rajagopalam S, Ranjan R, Kolli H, Singh M, Venuto R, et al Preoperative use of angiotensin-converting enzyme inhibitors/ angiotensin receptor blockers is associated with increased risk for acute kidney injury after cardiovascular surgery. Clin J Am Soc Nephrol 2008; 3:1266-73.
78. Ballermann BJ, Onuigbo MAC. Angiotensins. In: Fray JCS, ed. Handbook of Physiology, Section 7, The Endocrine System, Vol III. Endocrine Regulation of Water and Electrolyte Balance. New York, NY, Oxford University Press, 2000:104-55.
79. Zhang SL, Guo J, Moini B, Ingelfinger JR. Angiotensin II stimulates Pax-2 in rat kidney proximal tubular cells: Impact on proliferation and apoptosis. Kidney Int 2004; 66:2181-92.
80. Chen CO, Park MH, Forbes MS, Thornhill BA, Kiley SC, Yoo KH, et al Angiotensin Converting Enzyme inhibition aggravates renal interstitial injury resulting from partial unilateral ureteral obstruction in the neonatal rat. Am J Physiol Renal Physiol 2007; 292:F946-55.